 | Up a level |
Mark, Michael; Froesch, Patrizia; Gysel, Katrin; Rothschild, Sacha I; Addeo, Alfredo; Ackermann, Christoph J; Chiquet, Sabrina; Schneider, Martina; Ribi, Karin; Maranta, Angela Fischer; Bastian, Sara; von Moos, Roger; Joerger, Markus; Früh, Martin (2024). First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. European journal of cancer, 200(113600), p. 113600. Elsevier 10.1016/j.ejca.2024.113600
Joerger, Markus; Hundsberger, Thomas; Haefliger, Simon; von Moos, Roger; Hottinger, Andreas F; Kaindl, Thomas; Engelhardt, Marc; Marszewska, Michalina; Lane, Heidi; Roth, Patrick; Stathis, Anastasios (2023). Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. Investigational new drugs, 41(2), pp. 267-275. Springer 10.1007/s10637-023-01336-9
Mamot, Christoph; Wicki, Andreas; Hasler-Strub, Ursula; Riniker, Salome; Li, Qiyu; Holer, Lisa; Bärtschi, Daniela; Zaman, Khalil; von Moos, Roger; Dedes, Konstantin J; Boos, Laura A; Novak, Urban; Bodmer, Alexandre; Ritschard, Reto; Obermann, Ellen C; Tzankov, Alexandar; Ackermann, Christoph; Membrez-Antonioli, Véronique; Zürrer-Härdi, Ursina; Caspar, Clemens B; ... (2023). A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer. Scientific Reports, 13(1), p. 3705. Nature Publishing Group 10.1038/s41598-023-30950-z
Schmulenson, Eduard; Bovet, Cédric; Theurillat, Regula; Decosterd, Laurent Arthur; Largiadèr, Carlo R; Prost, Jean-Christophe; Csajka, Chantal; Bärtschi, Daniela; Guckenberger, Matthias; von Moos, Roger; Bastian, Sara; Joerger, Markus; Jaehde, Ulrich (2022). Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). British journal of clinical pharmacology, 88(12), pp. 5336-5347. Wiley-Blackwell 10.1111/bcp.15461
Wirsching, Hans-Georg; Roelcke, Ulrich; Weller, Jonathan; Hundsberger, Thomas; Hottinger, Andreas F; von Moos, Roger; Caparrotti, Francesca; Conen, Katrin; Remonda, Luca; Roth, Patrick; Ochsenbein, Adrian; Tabatabai, Ghazaleh; Weller, Michael (2021). MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. Clinical cancer research, 27(1), pp. 179-188. American Association for Cancer Research 10.1158/1078-0432.CCR-20-2096
Peters, Solange; Danson, Sarah; Hasan, Baktiar; Dafni, Urania; Reinmuth, Niels; Majem, Margarita; Tournoy, Kurt G; Mark, Michael T; Pless, Miklos; Cobo, Manuel; Rodriguez-Abreu, Delvys; Falchero, Lionel; Moran, Teresa; Ortega Granados, Ana Laura; Monnet, Isabelle; Mohorcic, Katja; Sureda, Bartomeu Massutí; Betticher, Daniel; Demedts, Ingel; Macias, Jose Antionio; ... (2020). A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. Journal of thoracic oncology, 15(10), pp. 1647-1656. Elsevier 10.1016/j.jtho.2020.06.011
Rothschild, Sacha I; Betticher, Daniel; Zenhäusern, Reinhard; Anchisi, Sandro; von Moos, Roger; Pless, Miklos; Moosmann, Peter; Popescu, Razvan A; Calderoni, Antonello; Dressler, Marco; Rauch, Daniel; Pederiva, Stefanie; Woelky, Regina; Papet, Claudia; Bühler, Vera; Borner, Markus (2019). Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study. Cancer chemotherapy and pharmacology, 84(4), pp. 881-889. Springer 10.1007/s00280-019-03927-x
Kienle, Dirk L.; Dietrich, Daniel; Ribi, Karin; Wicki, Andreas; Quagliata, Luca; Winterhalder, Ralph C.; Koeberle, Dieter; Horber, Daniel; Bastian, Sara; Kueng, Marc; Saletti, Piercarlo; Helbling, Daniel; Baertschi, Daniela; Lugli, Alessandro; Bernhard, Jürg; Andrieu, Christiane; von Moos, Roger (2019). Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. Journal of geriatric oncology, 10(2), pp. 304-310. Elsevier 10.1016/j.jgo.2018.11.011
von Moos, Roger; Koeberle, Dieter; Schacher, Sabina; Hayoz, Stefanie; Winterhalder, Ralph C; Roth, Arnaud; Bodoky, György; Samaras, Panagiotis; Berger, Martin D.; Rauch, Daniel; Saletti, Piercarlo; Plasswilm, Ludwig; Zwahlen, Daniel; Meier, Urs R; Yan, Pu; Izzo, Paola; Klingbiel, Dirk; Bärtschi, Daniela; Zaugg, Kathrin (2018). Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). European journal of cancer, 89, pp. 82-89. Elsevier 10.1016/j.ejca.2017.11.005
Zweifel, Martin; Thürlimann, Beat; Riniker, Salome; Weder, Patrik; von Moos, Roger; Pagani, Olivia; Bigler, Martin; Rothgiesser, Karin M; Pilop, Christiane; Hawle, Hanne; Brauchli, Peter; Tapia, Coya; Schoenfeld, Wolfgang; Sessa, Cristiana (2017). Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients. Endocrine Connections, 6(7), pp. 549-556. BioScientifica 10.1530/EC-17-0174
Pestalozzi, Bernhard C; Tausch, Christoph; Dedes, Konstantin J; Rochlitz, Christoph; Zimmermann, Stefan; von Moos, Roger; Winterhalder, Ralph; Ruhstaller, Thomas; Mueller, Andreas; Buser, Katharina; Borner, Markus; Novak, Urban; Nussbaum, Catrina Uhlmann; Seifert, Bettina; Bigler, Martin; Bize, Vincent; Vilei, Simona Berardi; Rageth, Christoph; Aebi, Stefan (2017). Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10). BMC cancer, 17(1), p. 265. BioMed Central 10.1186/s12885-017-3261-1
Borgquist, Signe; Giobbie-Hurder, Anita; Ahern, Thomas P; Garber, Judy E; Colleoni, Marco; Láng, István; Debled, Marc; Ejlertsen, Bent; von Moos, Roger; Smith, Ian; Coates, Alan S; Goldhirsch, Aron; Rabaglio, Manuela; Price, Karen N; Gelber, Richard D; Regan, Meredith M; Thürlimann, Beat (2017). Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. Journal of clinical oncology, 35(11), pp. 1179-1188. American Society of Clinical Oncology 10.1200/JCO.2016.70.3116
Driessen, Christoph; Kraus, Marianne; Joerger, Markus; Rosing, Hilde; Bader, Jürgen; Hitz, Felicitas; Berset, Catherine; Xyrafas, Alexandros; Hawle, Hanne; Berthod, Gregoire; Overkleeft, Hermann S; Sessa, Cristiana; Huitema, Alwin; Pabst, Thomas; von Moos, Roger; Hess, Dagmar; Mey, Ulrich J M (2016). Treatment with the HIV protease inhibitor Nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica - the hematology journal, 101(3), pp. 346-355. Ferrata-Storti Foundation 10.3324/haematol.2015.135780
Dummer, Reinhard; Siano, Marco; Hunger, Robert; Lindenblatt, Nicole; Braun, Ralph; Michielin, Oliver; Mihic-Probst, Daniela; von Moos, Roger; Najafi, Yousef; Guckenberger, Merlin; Arnold, Andreas (2016). The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. Swiss medical weekly, 146, w14279. EMH Schweizerischer Ärzteverlag 10.4414/smw.2016.14279
Pesce, Gianfranco A; Klingbiel, Dirk; Ribi, Karin; Zouhair, Abderahim; von Moos, Roger; Schlaeppi, Marc; Caspar, Clemens B; Fischer, Natalie; Anchisi, Sandro; Peters, Solange; Cathomas, Richard; Bernhard, Jürg; Kotrubczik, Nina M; D'Addario, Giannicola; Pilop, Christiane; Weber, Damien C; Bodis, Stephan; Pless, Miklos; Mayer, Michael and Stupp, Roger (2012). Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). European journal of cancer, 48(3), pp. 377-84. Amsterdam: Elsevier 10.1016/j.ejca.2011.10.016
Zappa, Francesco; Droege, Cornelia; Betticher, Daniel; von Moos, Roger; Bubendorf, Lukas; Ochsenbein, Adrian; Gautschi, Oliver; Oppliger Leibundgut, Elisabeth; Froesch, Patrizia; Stahel, Rolf; Hess, Thomas; Rauch, Daniel; Schmid, Petra; Mayer, Michael; Crowe, Susanne; Brauchli, Peter; Ribi, Karin; Pless, Miklos; on behalf of the Swiss Group for Clinical Cancer Research (SAKK), (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). Lung cancer, 78(3), pp. 239-44. Amsterdam: Elsevier 10.1016/S1359-6349(09)71860-9
Schoenewolf, Nicola L; Dummer, Reinhard; Mihic-Probst, Daniela; Moch, Holger; Simcock, Mathew; Ochsenbein, Adrian; Gillessen, Silke; Schraml, Peter; von Moos, Roger; Swiss Group for Clinical Cancer Research, (SAKK) (2012). Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. Case reports in oncology, 5(2), pp. 280-9. Basel: Karger 10.1159/000339300
Schraml, Peter; von Teichman, Adriana; Mihic-Probst, Daniela; Simcock, Mathew; Ochsenbein, Adrian; Dummer, Reinhard; Michielin, Olivier; Seifert, Bettina; Schläppi, Marc; Moch, Holger; von Moos, Roger (2012). Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncology reports, 28(2), pp. 654-8. Athens: National Hellenic Research Foundation 10.3892/or.2012.1826
Cathomas, Richard; Rothermundt, Christian; Klingbiel, Dirk; Bubendorf, Lukas; Jaggi, Rolf; Betticher, Daniel C; Brauchli, Peter; Cotting, Denise; Droege, Cornelia; Winterhalder, Ralph; Siciliano, Daniele; Berthold, Dominik R; Pless, Miklos; Schiess, Ralph; von Moos, Roger; Gillessen, Silke (2012). Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clinical cancer research, 18(21), pp. 6049-57. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-12-2219
Ruhstaller, Thomas; Pless, Miklos; Dietrich, Daniel; Kranzbuehler, Helmut; von Moos, Roger; Moosmann, Peter; Montemurro, Michael; Schneider, Paul M; Rauch, Daniel; Gautschi, Oliver; Mingrone, Walter; Widmer, Lucas; Inauen, Roman; Brauchli, Peter; Hess, Viviane (2011). Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). Journal of clinical oncology, 29(6), pp. 626-31. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2010.31.9715
Huober, Jens; Baumann, Michael; Rochlitz, Christoph; Aebi, Stefan; Güth, Uwe; von Moos, Roger; Müller, Andreas; von Rohr, Lukas; Widmer, Isabelle; Thürlimann, Beat (2011). Trastuzumab treatment beyond progression in advanced breast cancer: patterns of care in six Swiss breast cancer centers. Oncology - international journal of cancer research and treatment, 81(3-4), pp. 160-166. Karger 10.1159/000333396
Ruhstaller, Thomas; Templeton, Arnoud; Ribi, Karin; Schuller, Jan C; Borner, Markus; Thierstein, Sandra; von Moos, Roger; Pederiva, Stefanie; Lohri, Andreas; Lombriser, Norbert; von Briel, Christian; Koeberle, Dieter; Popescu, Razvan (2010). Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). Onkologie, 33(5), pp. 222-8. Basel: Karger 10.1159/000305094
Ribi, Karin; Koeberle, Dieter; Schuller, Jan C; Honegger, Hanspeter; Roth, Arnaud; Hess, Viviane; Moosmann, Peter; von Moos, Roger; Borner, Markus; Lombriser, Norbert; Pestalozzi, Bernhard; Ruhstaller, Thomas (2009). Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation? Supportive care in cancer, 17(8), pp. 1109-1116. Berlin: Springer 10.1007/s00520-008-0570-6
Klaeser, Bernd; Nitzsche, Egbert; Schuller, Jan C; Köberle, Dieter; Widmer, Lucas; Balmer-Majno, Sabine; Hany, Thomas; Cescato-Wenger, Corinne; Brauchli, Peter; Zünd, Michael; Pestalozzi, Bernhard C; Caspar, Clemens; Albrecht, Susanne; von Moos, Roger; Ruhstaller, Thomas (2009). Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). Onkologie, 32(12), pp. 724-30. Basel: Karger 10.1159/000251842
Glaus, Agnes; Boehme, Christel; Thürlimann, Beat; Ruhstaller, Thomas; Hsu, Shu-Fang; Morant, Rudolf; Senn, Hans-Jörg; von Moos, Roger (2006). Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Annals of oncology, 17(5), pp. 801-806. Oxford: Oxford University Press 10.1093/annonc/mdl030
